Sign up for our complimentary
weekly e-journal

Main Newsletter
Mastery Series
Therapy Series
 
Bookmark and Share | Print Article | Items for the Week Previous | All Articles This Week | Next
This article originally posted and appeared in  CardiovascularMedicationIssue 640

Statins Can Reduce the Risk of Pancreatitis by 23%

A meta-analysis of 21 trials showed that the risk of pancreatic inflammation was reduced in patients with normal or mildly increased triglycerides when they took statin drugs.... 

Advertisement

According to David Preiss, MD, PhD, of the University of Glasgow in Scotland, pooled data from 113,800 participants in studies comparing placebo with standard-dose statins indicated that the risk of pancreatitis was lower by 23% (relative risk 0.77, 95% CI 0.62 to 0.97, P=0.03).

In addition, data from five trials of intensive versus moderate statin dosing, with a total of about 40,000 patients, showed a lower incidence of pancreatitis with high doses, although the difference did not reach statistical significance (RR 0.82, 95% CI 0.59 to 1.12, P=0.21).

A third analysis of seven placebo-controlled trials of fibrate drugs showed no such relationship, Preiss and colleagues found. In fact, the data from some 40,000 trial participants showed a trend toward increased risk of pancreatitis with fibrates (RR 1.39, 95% CI 1.00 to 1.95, P=0.053).

The findings on statins contradict a number of previous case reports and epidemiologic studies that had suggested increased risk of pancreatic inflammation with statins.

Preiss and colleagues wrote, "Although we cannot completely exclude the possibility that statin therapy may lead to very occasional idiosyncratic cases of pancreatitis, the randomized trial data appear reassuring." They also noted that animal studies have shown that statins may actually alleviate acute and chronic pancreatitis.

Preiss and colleagues reviewed the literature for controlled trials of statins with at least 1,000 participants, in which numbers of pancreatitis cases were either reported or could be obtained directly from the investigators.

A total of 21 trials met the inclusion criteria. Median follow-up in these studies ranged from 1.9 to 6.7 years. The largest was the so-called Heart Protection Study, reported in 2002, with more than 20,000 patients; the smallest was GREACE, published the same year, with 1,600 participants.

The same criteria were applied to trials of fibrates, yielding seven trials. Six of them involved monotherapy with clofibrate, gemfibrozil, bezafibrate, or fenofibrate. The seventh was the ACCORD Lipid study that tested a combination of fenofibrate plus simvastatin versus the statin drug and placebo. Most of the studies excluded patients with very high triglycerides. Mean baseline triglyceride levels ranged from 118 to 187 mg/dL.

Relatively few pancreatitis cases were seen in the trials -- among the nearly 200,000 patients in all the trials, a total of 608 developed the condition. Not surprisingly, none of the individual trials showed a significant difference in pancreatitis risk with the interventional drug treatment versus placebo or active control. But some showed strong trends suggestive of a protective statin effect.

However, because of the small numbers of pancreatitis cases identified in the studies, the researchers cautioned that their findings should be regarded as "hypothesis-generating" for statins as well as fibrates. They also recommended that a trial of statins versus fibrates in patients with severely elevated triglycerides "would be clinically valuable."

Practice Pearls:
  • Note that an analysis of seven placebo-controlled trials of fibrate drugs showed no reduction in the rate of pancreatitis.
  • The risk of pancreatic inflammation was reduced in patients with normal or mildly increased triglycerides when they took statin drugs.

Preiss D, et al "Lipid-modifying therapies and risk of pancreatitis: a meta-analysis" JAMA 2012; 308: 804-811. Aug. 22, 2012 

Advertisement


 

Bookmark and Share | Print | Category | Home

This article originally posted 23 August, 2012 and appeared in  CardiovascularMedicationIssue 640

Past five issues: Diabetes Clinical Mastery Series Issue 242 | Issue 782 | Diabetes Clinical Mastery Series Issue 241 | issue 781 | Diabetes Clinical Mastery Series Issue 240 |

2015 Most Popular Articles:

Neuropathy Due to Vitamin B-12 Deficiency, Not Diabetes
Posted April 30, 2015
What Is the Medicare Diabetes Prevention Act?
Posted May 08, 2015
Is Diet or Exercise the Best Way to Reduce Diabetes Risk?
Posted May 15, 2015
Fish Oil May Help with Diabetic Neuropathy
Posted May 15, 2015
Metformin Reported in Use with Only 3.7% of Those with Prediabetes
Posted April 30, 2015
SGLT-2 Inhibitors: Teach from the Start and Manage Expectations
Posted May 03, 2015
GLP-1 Analog May Help with NAFLD and Nonalcoholic Steatohepatitis
Posted May 15, 2015
Summary of Standards of Care for Diabetes for Primary Care
Posted April 30, 2015
Treating Sleep Apnea with CPAP Nightly Can Lower Diabetes Risk
Posted May 08, 2015
Statin Therapy Associated with 46% Higher Risk of Type 2 Diabetes
Posted April 23, 2015


Browse by Feature Writer & Article Category.
A. Lee Dellon, MD | Aaron I. Vinik, MD, PhD, FCP, MACP | Beverly Price | Charles W Martin, DD | Derek Lowe, PhD | Dr. Brian Jakes, Jr. | Dr. Fred Pescatore | Dr. Tom Burke, Ph.D | Eric S. Freedland | Evan D. Rosen | Ginger Kanzer-Lewis | Greg Milliger | Kristina Sandstedt | Laura Plunkett | Leonard Lipson, M.A. | Louis H. Philipson | Maria Emanuel Ryan, DDS, PhD | Marilyn Porter, RD, CDE | Melissa Diane Smith | Michael R. Cohen, RPh, MS, ScD, FASHP | Paul Chous, M.A., OD | Philip A. Wood PhD | R. Keith Campbell, Professor, B.Pharm, MBA, CDE | Richard K. Bernstein, MD | Sheri R. Colberg PhD | Sherri Shafer | Stanley Schwartz, MD, FACP, FACE | Steve Pohlit | Steven V. Edelman, M.D. | Timothy S. Hollingshead |

Cast Your Vote
Do you believe that we could have a bionic pancreas by 2017?
CME/CE of the Week
William Tamborlane, MD, FAAP, FACE

Category: General Diabetes
Credits:
 .75
Search Articles On Diabetes In Control